145 related articles for article (PubMed ID: 17273184)
1. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells.
Goding S; Yang Q; Mi Z; Robbins PD; Basse PH
Cancer Gene Ther; 2007 May; 14(5):441-50. PubMed ID: 17273184
[TBL] [Abstract][Full Text] [Related]
2. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
3. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
4. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.
Nannmark U; Hokland ME; Agger R; Christiansen M; Kjaergaard J; Goldfarb RH; Bagge U; Unger M; Johansson BR; Albertsson PA; Basse PH
In Vivo; 2000; 14(5):651-8. PubMed ID: 11125549
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells and gene therapy: potential of gene transfection for optimizing effector cell functions and for targeting gene products into tumor metastases.
Goldfarb RH; Whiteside TL; Basse PH; Lin WC; Vujanovic N; Herberman RB
Nat Immun; 1994; 13(2-3):131-40. PubMed ID: 8173234
[TBL] [Abstract][Full Text] [Related]
6. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].
Li SP; Urban FA; Macgregor JN; Hughes DP; McDonagh KT
Ai Zheng; 2004 Nov; 23(11 Suppl):1370-5. PubMed ID: 15566639
[TBL] [Abstract][Full Text] [Related]
7. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
Fujita T; Timme TL; Tabata K; Naruishi K; Kusaka N; Watanabe M; Abdelfattah E; Zhu JX; Ren C; Ren C; Yang G; Goltsov A; Wang H; Vlachaki MT; Teh BS; Butler EB; Thompson TC
Gene Ther; 2007 Feb; 14(3):227-36. PubMed ID: 17024109
[TBL] [Abstract][Full Text] [Related]
8. Cytokine gene therapy using adenovirally transduced, tumor-seeking activated natural killer cells.
Goding SR; Yang Q; Knudsen KB; Potter DM; Basse PH
Hum Gene Ther; 2007 Aug; 18(8):701-11. PubMed ID: 17678438
[TBL] [Abstract][Full Text] [Related]
9. Tracking of green fluorescent protein (GFP)-labeled LAK cells in mice carrying B16 melanoma metastases.
Takashima K; Fujiwara H; Inada S; Atsuji K; Araki Y; Kubota T; Yamagishi H
Anticancer Res; 2006; 26(5A):3327-32. PubMed ID: 17094448
[TBL] [Abstract][Full Text] [Related]
10. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
11. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.
Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Miyagi T; Jinushi M; Sakamori R; Kohga K; Uemura A; Ohkawa K; Storkus WJ; Hayashi N
Gene Ther; 2007 Jun; 14(11):863-71. PubMed ID: 17344900
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
13. An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation.
Zhu L; Zhao Z; Wei Y; Marcotte W; Wagner TE; Yu X
Int J Oncol; 2012 Aug; 41(2):661-9. PubMed ID: 22581115
[TBL] [Abstract][Full Text] [Related]
14. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model.
Satoh T; Saika T; Ebara S; Kusaka N; Timme TL; Yang G; Wang J; Mouraviev V; Cao G; Fattah el MA; Thompson TC
Cancer Res; 2003 Nov; 63(22):7853-60. PubMed ID: 14633713
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases.
Hirschowitz EA; Crystal RG
Am J Respir Cell Mol Biol; 1999 May; 20(5):935-41. PubMed ID: 10226063
[TBL] [Abstract][Full Text] [Related]
16. Addition of interleukin 12 to low dose interleukin 2 treatment improves antitumor efficacy in vivo.
Leder GH; Oppenheim M; Rosenstein M; Lotze MT; Beger HG
Z Gastroenterol; 1995 Sep; 33(9):499-502. PubMed ID: 8525651
[TBL] [Abstract][Full Text] [Related]
17. Combination nonviral cytokine gene therapy for head and neck cancer.
Li D; Zeiders JW; Liu S; Guo M; Xu Y; Bishop JS; O'Malley BW
Laryngoscope; 2001 May; 111(5):815-20. PubMed ID: 11368072
[TBL] [Abstract][Full Text] [Related]
18. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.
Basse PH
APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S
Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778
[TBL] [Abstract][Full Text] [Related]
20. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]